Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan
July 17, 2017 08:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., July 17, 2017 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) announced today that on July 14, 2017, BP Peptides, LLC (“Brookstone”) purchased 13,500,000...
Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period
February 03, 2016 15:29 ET
|
Capstone Therapeutics
TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period
December 15, 2015 16:15 ET
|
Capstone Therapeutics
TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides
October 14, 2015 09:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced...
Capstone Therapeutics Announces Second Quarter 2015 Financial Results and Operating Update Conference Call
August 10, 2015 11:36 ET
|
Capstone Therapeutics
TEMPE, Ariz., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), will hold a conference call and webcast on Thursday, August 13, 2015 at 4:30 pm EDT. The call may...
Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
July 23, 2015 08:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., July 23, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the...